Literature DB >> 31899203

Validation of a Comprehensive Clinical Algorithm for the Assessment and Treatment of Microbial Keratitis.

Lawson Ung1, Yvonne Wang2, Mark Vangel3, Emma C Davies2, Matthew Gardiner2, Paulo J M Bispo1, Michael S Gilmore4, James Chodosh5.   

Abstract

PURPOSE: To validate a comprehensive clinical algorithm for the assessment and treatment of microbial keratitis (MK).
DESIGN: Retrospective cohort study.
METHODS: The "1, 2, 3 Rule" for the initial management of MK was conceived by Vital and associates in 2007 to inform the decision as to when to perform corneal cultures. The rule is invoked when any 1 of 3 clinical parameters is met: ≥1+ anterior chamber cells, ≥2 mm infiltrate, or infiltrate ≤3 mm distance from the corneal center. When the rule is met, we added the mandatory use of fortified topical antibiotics after cultures are obtained. We compared outcomes of cases presenting to Massachusetts Eye and Ear 2 years before (Group I, n = 665) and after (Group II, n = 767) algorithm implementation. The primary composite outcome was a vision-threatening complication, such as corneal perforation.
RESULTS: At a median follow-up of 67.0 and 60.0 days, respectively, 172 patients experienced a vision-threatening complication (Group I, 12.9% vs Group II, 11.2%, P = .51). While the algorithm codified conventional management practice at either end of disease severity, the effect of algorithm-augmented care was best appreciated in patients with lesions satisfying only 1 criterion. In this group, there was an increase in the proportion of patients undergoing culture at presentation (54.6% vs 67.7%, P = .006), fortified antibiotic prescription (29.7% vs 53.9%, P < .001), and reduction in vision-threatening complications (9.7% vs 1.8%, P = .001). The proportion of patients who were not cultured at presentation but later required culturing decreased (13.4% vs 5.1%, P = .001), as did patients who did not meet any criteria but were nonetheless cultured (23.9% vs 8.5%, P < .001). Multiple logistic regression showed that all algorithm parameters were independently associated with outcome: ≥1+ anterior chamber cells (odds ratio [OR] 1.66, 95% confidence interval 1.09-2.52); ≥2 mm infiltrate (OR 4.74, 2.68-8.40); and ≤3 mm from corneal center (OR 2.82, 1.85-4.31), confirmed with comparison to a bootstrapped sample (n = 10,000).
CONCLUSIONS: The implementation of this algorithm reduced vision-threatening complications for patients with lesions satisfying only 1 criterion, arguably the most difficult patients in whom to judge disease severity. Implementation also led to a decrease in patients receiving unnecessary care.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31899203     DOI: 10.1016/j.ajo.2019.12.019

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Risk Factors, Clinical Outcomes, and Prognostic Factors of Bacterial Keratitis: The Nottingham Infectious Keratitis Study.

Authors:  Darren Shu Jeng Ting; Jessica Cairns; Bhavesh P Gopal; Charlotte Shan Ho; Lazar Krstic; Ahmad Elsahn; Michelle Lister; Dalia G Said; Harminder S Dua
Journal:  Front Med (Lausanne)       Date:  2021-08-11

Review 2.  Post-keratoplasty Infectious Keratitis: Epidemiology, Risk Factors, Management, and Outcomes.

Authors:  Anna Song; Rashmi Deshmukh; Haotian Lin; Marcus Ang; Jodhbir S Mehta; James Chodosh; Dalia G Said; Harminder S Dua; Darren S J Ting
Journal:  Front Med (Lausanne)       Date:  2021-07-07

3.  Novel Molecular Barcoding for Rapid Pathogen Detection in Infectious Keratitis.

Authors:  Lawson Ung; Nicole L Belanger; James Chodosh; Michael S Gilmore; Paulo J M Bispo
Journal:  Ophthalmol Sci       Date:  2021-09-29

Review 4.  Foundational concepts in the biology of bacterial keratitis.

Authors:  Lawson Ung; James Chodosh
Journal:  Exp Eye Res       Date:  2021-06-05       Impact factor: 3.770

5.  First report of a new corneal pathogen: Phaeoacremonium parasiticum.

Authors:  Horace Massa; Arnaud Riat; Georgios D Panos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-07-12       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.